5-(4-amino-7-isobutyl-6,7-dihydropyrrolo[3,2-d]pyrimidin-5-yl)-1,3-benzoxazol-2-amine

ID: ALA5220500

PubChem CID: 142608609

Max Phase: Preclinical

Molecular Formula: C17H20N6O

Molecular Weight: 324.39

Names and Identifiers

Canonical SMILES:  CC(C)CC1CN(c2ccc3oc(N)nc3c2)c2c(N)ncnc21

Standard InChI:  InChI=1S/C17H20N6O/c1-9(2)5-10-7-23(15-14(10)20-8-21-16(15)18)11-3-4-13-12(6-11)22-17(19)24-13/h3-4,6,8-10H,5,7H2,1-2H3,(H2,19,22)(H2,18,20,21)

Standard InChI Key:  UUWNQXUHQXRBNH-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 27  0  0  0  0  0  0  0  0999 V2000
   -1.6910   -0.0290    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9765   -0.4415    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1919   -0.1866    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0630    0.5980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8700    0.7695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1249    1.5542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8786    1.8898    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7924    2.7102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4055    3.2623    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9854    2.8818    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.5728    2.1673    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2340    1.9957    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4889    1.2111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2929   -0.8540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1919   -1.5215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0630   -2.3061    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8700   -2.4776    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4220   -1.8645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1249   -3.2623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9765   -1.2665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6910   -1.6790    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4055   -1.2665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4055   -0.4415    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6910    0.7962    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  8 10  1  0
 10 11  1  0
  6 11  1  0
 11 12  2  0
 12 13  1  0
 13  4  2  0
  3 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 17 19  1  0
 15 20  1  0
  2 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23  1  2  0
  1 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5220500

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 324.39

Molecular Weight (Monoisotopic): 324.1699

AlogP: 3.06

#Rotatable Bonds: 3

Polar Surface Area: 107.09

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 5.73

CX LogP: 2.47

CX LogD: 2.46

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.76

Np Likeness Score: -0.40

References

1. Oleksak P, Nepovimova E, Chrienova Z, Musilek K, Patocka J, Kuca K..  (2022)  Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).,  238  [PMID:35688004] [10.1016/j.ejmech.2022.114498]

Source

Source(1):

• Scientific Literature